Sebastian Palmqvist

List of Publications by Year in Descending Order

123 papers	**5,646** citations	**36** h-index	**74** g-index
154 ext. papers	**8,426** ext. citations	**8** avg, IF	**6.01** L-index

#	Paper	IF	Citations
123	*Neurology*, **2022**,	6.5	3
122	Components of gait in people with and without mild cognitive impairment.. *Gait and Posture*, **2022**, 93, 83-89	2.6	
121	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.. *Movement Disorders*, **2022**,	7	1
120	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.. *Alzheimer's Research and Therapy*, **2022**, 14, 46	9	1
119	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.. *JAMA Neurology*, **2021**,	17.2	10
118	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. *Alzheimer's and Dementia*, **2021**, 17,	1.2	3
117	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. *Scientific Reports*, **2021**, 11, 19853	4.9	0
116	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. *Brain*, **2021**, 144, 2771-2783	11.2	10
115	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. *Alzheimer's and Dementia*, **2021**, 17, 1832-1842	1.2	0
114	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. *Nature Medicine*, **2021**, 27, 1034-1042	50.5	56
113	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. *EMBO Molecular Medicine*, **2021**, 13, e14022	12	22
112	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. *Brain*, **2021**, 144, 2826-2836	11.2	12
111	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A42/A40 and p-tau. *Alzheimer's and Dementia*, **2021**,	1.2	12
110	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. *Nature Communications*, **2021**, 12, 3555	17.4	23
109	A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nature Communications*, **2021**, 12, 3400	17.4	51
108	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. *EMBO Molecular Medicine*, **2021**, 13, e14398	12	8
107	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, 683-691	6.4	2

106	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ɛ4, sex and age. *Progress in Neurobiology*, **2021**, 198, 101904	10.9	8
105	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. *Nature Aging*, **2021**, 1, 114-123		34
104	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 149-156	17.2	62
103	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2245-2258	8.8	8
102	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. *Translational Psychiatry*, **2021**, 11, 76	8.6	32
101	Biomarker testing in MCI patients-deciding who to test. *Alzheimer's Research and Therapy*, **2021**, 13, 14	9	0
100	Plasma GFAP is an early marker of amyloid-ß but not tau pathology in Alzheimer's disease. *Brain*, **2021**,	11.2	31
99	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. *JAMA Neurology*, **2021**, 78, 961-971	17.2	29
98	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. *Neurology*, **2021**, 97, e1681-e1694	6.5	10
97	Association of CSF Aß38 Levels With Risk of Alzheimer Disease-Related Decline.. *Neurology*, **2021**,	6.5	2
96	Blood-based biomarkers for Alzheimer's disease. *EMBO Molecular Medicine*, **2021**, e14408	12	7
95	Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e053556	1.2	
94	Coping Styles among People with Parkinson's Disease: A Three-Year Follow-Up Study. *Behavioral Sciences (Basel, Switzerland)*, **2020**, 10,	2.3	3
93	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that are impacted by APOE ɛ4, sex and age but not pathology. *Alzheimer's and Dementia*, **2020**, 16, e040745	1.2	
92	Genome-wide polygenic risk scores for identification of gene therapeutic target. *Alzheimer's and Dementia*, **2020**, 16, e040903	1.2	
91	Health utility in preclinical and prodromal AD compared to controls: EQ5D data from the Swedish Biofinder Study. *Alzheimer's and Dementia*, **2020**, 16, e041032	1.2	
90	Biomarker testing in MCI patients: Deciding who to tap. *Alzheimer's and Dementia*, **2020**, 16, e042735	1.2	
89	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. *Nature Communications*, **2020**, 11, 6252	17.4	15

88   Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline. *Journal of Alzheimer's Disease*, **2020**, 75, 1191-1201   4.3   13

87   Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. *JAMA Neurology*, **2020**, 77, 955-965   17.2   71

86   The implications of different approaches to define AT(N) in Alzheimer disease. *Neurology*, **2020**, 94, e2233-e2244   8.5   34

85   Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. *NeuroImage: Clinical*, **2020**, 27, 102310   5.3   5

84   Mild to Moderate Cognitive Impairment Does Not Affect the Ability to Self-Report Important Symptoms in Patients With Cancer: A Prospective Longitudinal Multinational Study (EPCCS). *Journal of Pain and Symptom Management*, **2020**, 60, 346-354.e2   4.8   3

83   The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. *Alzheimer's Research and Therapy*, **2020**, 12, 30   9   6

82   Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. *JAMA Neurology*, **2020**, 77, 632-642   17.2   36

81   Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nature Medicine*, **2020**, 26, 379-386   58.5   292

80   Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. *Nature Communications*, **2020**, 11, 1683   17.4   133

79   Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. *Science Advances*, **2020**, 6, eaaz2387   14.3   88

78   The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. *Brain*, **2020**, 143, 3805-3815   11.2   18

77   Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, 335-344   1.2   31

76   Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. *Brain*, **2020**, 143, 3234-3241   11.2   63

75   Derivation and utility of an Aβ PET pathology accumulation index to estimate Aβ load. *Neurology*, **2020**, 95, e2834-e2844   6.5   3

74   Unburdening dementia - a basic social process grounded theory based on a primary care physician survey from 25 countries. *Scandinavian Journal of Primary Health Care*, **2020**, 38, 253-264   2.7   4

73   Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA - Journal of the American Medical Association*, **2020**, 324, 772-781   27.4   268

72   Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurology, The*, **2020**, 19, 422-433   24.1   286

71   Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *Lancet Neurology, The*, **2019**, 18, 1034-1044   24.1   45

70	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related βAmyloid Status. *JAMA Neurology*, **2019**, 76, 1060-1069	17.2	159
69	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. *Cerebral Cortex*, **2019**, 29, 2173-2182	5.1	19
68	βamyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. *Scientific Reports*, **2019**, 9, 11180	4.9	15
67	Determining clinically meaningful decline in preclinical Alzheimer disease. *Neurology*, **2019**, 93, e322-e333	6.5	40
66	Staging βAmyloid Pathology With Amyloid Positron Emission Tomography. *JAMA Neurology*, **2019**, 76, 1319-1329	17.2	71
65	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Molecular Medicine*, **2019**, 11, e11170	12	113
64	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. *Scientific Reports*, **2019**, 9, 15417	4.9	5
63	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. *ELife*, **2019**, 8,	8.9	27
62	Relating Experienced To Recalled breathlessness Observational (RETRO) study: a prospective study using a mobile phone application. *BMJ Open Respiratory Research*, **2019**, 6, e000370	5.6	3
61	DT-01-04: DIAGNOSTIC PERFORMANCE OF [18F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER-2 STUDY **2019**, 15, P1485-P1486		
60	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. *Alzheimer's Research and Therapy*, **2019**, 11, 109	9	9
59	Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. *Neurology*, **2019**, 92, e395-e405	6.5	16
58	Associations between tau, Aβand cortical thickness with cognition in Alzheimer disease. *Neurology*, **2019**, 92, e601-e612	6.5	125
57	Accurate risk estimation of βamyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. *Alzheimer's and Dementia*, **2019**, 15, 194-204	1.2	31
56	Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. *Neurology*, **2018**, 90, e388-e395	6.5	62
55	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. *Cerebral Cortex*, **2018**, 28, 340-349	5.1	18
54	Cerebral hypoperfusion is not associated with an increase in amyloid βpathology in middle-aged or elderly people. *Alzheimer's and Dementia*, **2018**, 14, 54-61	1.2	13
53	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. *Neurology*, **2018**, 91, e867-e877	6.5	120

52 — Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. *Neurobiology of Aging*, **2018**, 71, 81-90 — 5.6 — 8

51 — Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study. *Alzheimer's Research and Therapy*, **2018**, 10, 77 — 9 — 36

50 — P3-492: THE MISINTERPRETED AGE EFFECT ON COGNITIVE TEST RESULTS: A PRESENTATION OF TEST NORMS FROM PERSONS WITHOUT UNDERLYING PATHOLOGIES **2018**, 14, P1310-P1310

49 — P4-078: CONCORDE-AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE **2018**, 14, P1465-P1465

48 — O3-14-05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION **2018**, 14, P1061-P1061

47 — DT-01-06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS **2018**, 14, P1667-P1668

46 — P1-430: EFFECTS OF APOE ε4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE **2018**, 14, P473-P474

45 — O2-15-04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS **2018**, 14, P661-P662

44 — F1-04-01: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NON-DEMENTED ELDERLY SUBJECTS **2018**, 14, P206-P206

43 — P1-373: BETA-AMYLOID AND WHITE MATTER LESIONS ARE INDEPENDENTLY ASSOCIATED WITH HIPPOCAMPAL ATROPHY AND REDUCED CORTICAL TEMPORAL THICKNESS **2018**, 14, P439-P439

42 — O3-04-01: ASSOCIATIONS BETWEEN TAU, Aβ AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE **2018**, 14, P1018-P1019

41 — DT-02-04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA Aβ BIOMARKER ASSAYS **2018**, 14, P1670-P1670 — 1

40 — IC-P-036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NON-DEMENTED ELDERLY SUBJECTS **2018**, 14, P39-P39

39 — O2-09-01: CSF, PLASMA AND MRI BIOMARKER TRAJECTORIES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE **2018**, 14, P641-P641

38 — Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA - Journal of the American Medical Association*, **2018**, 320, 1151-1162 — 27.4 — 173

37 — Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. *Nature Communications*, **2017**, 8, 1214 — 17.4 — 348

36 — F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. *EMBO Molecular Medicine*, **2017**, 9, 1212-1223 — 12 — 124

35 — [P3-384]: THE MONTREAL COGNITIVE ASSESSMENT: NORMATIVE DATA FROM A LARGE SWEDISH POPULATION-BASED COHORT **2017**, 13, P1051-P1052

34	[O2-01-02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSS-VALIDATED METHOD THAT PREDICTS CEREBRAL AMYLOIDOSIS **2017**, 13, P548		
33	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. *Brain*, **2017**, 140, 2286-2294	11.2	94
32	The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort. *Journal of Alzheimer's Disease*, **2017**, 59, 893-901	4.3	82
31	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and A Pathology in Non-demented Individuals. *Frontiers in Aging Neuroscience*, **2017**, 9, 306	5.3	22
30	Assessing risk for preclinical amyloid pathology with , cognitive, and demographic information. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 4, 76-84	5.2	36
29	Plasma amyloid in Alzheimer's disease and vascular disease. *Scientific Reports*, **2016**, 6, 26801	4.9	290
28	Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral amyloidosis. *Nature Communications*, **2016**, 7, 10918	17.4	39
27	CSF A42/A40 and A42/A38 ratios: better diagnostic markers of Alzheimer disease. *Annals of Clinical and Translational Neurology*, **2016**, 3, 154-65	5.3	244
26	Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. *Brain*, **2016**, 139, e61	11.2	4
25	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. *EMBO Molecular Medicine*, **2016**, 8, 1184-1196	12	152
24	O2-08-06: CSF Analysis Detects Cerebral B-Amyloid Accumulation Earlier than Amyloid Pet **2016**, 12, P246-P247		
23	Cerebrospinal fluid analysis detects cerebral amyloid-accumulation earlier than positron emission tomography. *Brain*, **2016**, 139, 1226-36	11.2	229
22	Plasma tau in Alzheimer disease. *Neurology*, **2016**, 87, 1827-1835	6.5	269
21	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. *Neurology*, **2015**, 85, 1240-9	6.5	192
20	O1-07-01: Diagnostic comparison of regional amyloid PET and different CSF biomarker assays for identifying early Alzheimer's disease **2015**, 11, P140-P140		
19	A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years. *International Psychogeriatrics*, **2014**, 1-8	3.4	8
18	P2-290: BIOMARKERS FOR IDENTIFYING NEURODEGENERATIVE DISORDERS EARLY AND RELIABLY (BIOFINDER): METHODOLOGY AND PRELIMINARY RESULTS OF A NEW LARGE PROSPECTIVE COHORT STUDY **2014**, 10, P583-P584		
17	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. *Alzheimer's Research and Therapy*, **2014**, 6, 41	9	30

16	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. *JAMA Neurology*, **2014**, 71, 1282-9	17.2	254
15	Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. *JAMA Psychiatry*, **2014**, 71, 1183-91	14.5	65
14	Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders Extra*, **2013**, 3, 113-22	2.5	18
13	Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. *BMC Neurology*, **2013**, 13, 140	3.1	24
12	Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. *PLoS ONE*, **2012**, 7, e38639	3.7	56
11	Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia. *Current Alzheimer Research*, **2012**, 9, 257-66	3	15
10	Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2011**, 32, 417-23	2.6	27
9	A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2010**, 2, 29	9	25
8	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. *International Journal of Geriatric Psychiatry*, **2009**, 24, 1405-12	3.9	61
7	The usefulness of cube copying for evaluating treatment of Alzheimer's disease. *American Journal of Alzheimer's Disease and Other Dementias*, **2008**, 23, 439-46	2.5	8
6	Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment		1
5	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease		1
4	Plasma glial fibrillary acidic protein is an early marker of Aβ pathology in Alzheimer's disease		2
3	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau		3
2	CSF Aβ38 levels are associated with Alzheimer-related decline: implications for β-secretase modulators		1
1	Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly		1